Search
18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels
This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches
Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher
The aim of this study is to identify and quantify the preferences of patients with cystic fibrosis regarding treatment outcomes
Agreement between the DDD and vial-based measures of use supports the use of DDD for select antibiotics that may be targeted by antimicrobial stewardship programs
Head, Infectious Disease Implementation Research
Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)
This paper examines the use of a new antibiotic to treat diarrhoea cause by Cryptosporidium infection in Australian Indigenous children.
Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...